Autobahn Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)-- Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced that Kevin Finney, President and Chief Executive Officer, will participate in two upcoming investor conferences:

Evercore ISI’s 2024 Emerging Private Biotech Conference
Company Presentation: Thursday, February 29, 2024, at 1:05 p.m. ET
Location: Virtual

TD Cowen’s 44th Annual Health Care Conference
Investor Meetings: Wednesday, March 6, 2024
Location: Marriott Copley Place, Boston, MA

About Autobahn Therapeutics
Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neurodegenerative clinical candidates leveraging its brain-targeting chemistry platform. Autobahn aims to unlock new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. The company’s pipeline is led by ABX-002, a thyroid hormone receptor beta (TRβ) agonist, being developed as a potential adjunctive treatment for people with MDD, including those who have had an inadequate response to their antidepressant. Autobahn Therapeutics is based in San Diego. For more information, visit www.autobahntx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240222686198/en/

Bill Slattery, Jr.
THRUST Strategic Communications
[email protected]

Source: Autobahn Therapeutics

You May Also Be Interested In

• Ahtna Unveils New Enterprise Operations Rebranding
• Simply Good Foods Company Securities Fraud Class Action Result of Undisclosed Acquisition Failures and Over 27% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC
• Cogent Communications Holdings Securities Fraud Class Action Result of Undisclosed Demand and Backlog Issues and approximately 29% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick